SG10201906696RA - Anti-transthyretin antibodies - Google Patents
Anti-transthyretin antibodiesInfo
- Publication number
- SG10201906696RA SG10201906696RA SG10201906696RA SG10201906696RA SG10201906696RA SG 10201906696R A SG10201906696R A SG 10201906696RA SG 10201906696R A SG10201906696R A SG 10201906696RA SG 10201906696R A SG10201906696R A SG 10201906696RA SG 10201906696R A SG10201906696R A SG 10201906696RA
- Authority
- SG
- Singapore
- Prior art keywords
- ttr
- antibodies
- transthyretin
- accumulation
- amyloidosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
ANTI-TRANSTHYRETIN ANTIBODIES The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications. FIG. 96
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109004P | 2015-01-28 | 2015-01-28 | |
| US201562266555P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201906696RA true SG10201906696RA (en) | 2019-08-27 |
Family
ID=55300737
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706126WA SG11201706126WA (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
| SG10201906696RA SG10201906696RA (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706126WA SG11201706126WA (en) | 2015-01-28 | 2016-01-28 | Anti-transthyretin antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20160257737A1 (en) |
| EP (1) | EP3250593B1 (en) |
| JP (1) | JP7101927B2 (en) |
| KR (1) | KR102649788B1 (en) |
| CN (1) | CN107406500B (en) |
| AU (1) | AU2016210889C1 (en) |
| BR (1) | BR112017016345A2 (en) |
| CA (1) | CA2974993A1 (en) |
| CO (1) | CO2017008482A2 (en) |
| CU (1) | CU20170098A7 (en) |
| DK (1) | DK3250593T3 (en) |
| EA (1) | EA036014B1 (en) |
| ES (1) | ES2925716T3 (en) |
| HR (1) | HRP20220918T1 (en) |
| HU (1) | HUE059592T2 (en) |
| MX (1) | MX2017009803A (en) |
| MY (1) | MY193701A (en) |
| PE (1) | PE20180218A1 (en) |
| PL (1) | PL3250593T3 (en) |
| PT (1) | PT3250593T (en) |
| RS (1) | RS63513B1 (en) |
| SA (1) | SA517381981B1 (en) |
| SG (2) | SG11201706126WA (en) |
| SI (1) | SI3250593T1 (en) |
| TW (2) | TWI769570B (en) |
| WO (1) | WO2016120811A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3478716A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| SG11202002489YA (en) * | 2017-10-06 | 2020-04-29 | Prothena Biosciences Ltd | Anti-transthyretin antibodies |
| JOP20200132A1 (en) | 2017-11-29 | 2022-10-30 | Prothena Biosciences Ltd [Ie/Ie] | Lyophilized formulation of a monoclonal antibody against transthyretin |
| US20210230257A1 (en) * | 2018-06-26 | 2021-07-29 | Mor Research Applications | Transthyretin antibodies and uses thereof |
| CN111018976B (en) * | 2018-10-10 | 2022-04-01 | 东莞市朋志生物科技有限公司 | Recombinant antibody of anti-human cardiac troponin I |
| CA3118618A1 (en) * | 2018-11-09 | 2020-05-14 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| CN114127125A (en) * | 2019-07-08 | 2022-03-01 | 安进公司 | Multispecific thyroxin transporter immunoglobulin fusions |
| CN116804186B (en) * | 2023-07-05 | 2023-12-22 | 中国兽医药品监察所 | Anti-chicken infectious anemia virus monoclonal antibody hybridoma cell strain, monoclonal antibody, reagent or kit and application thereof |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (en) | 1982-01-22 | 1985-10-31 | Sandoz Ag | METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| DE69230142T2 (en) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BINDING PAIRS |
| ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JP3720353B2 (en) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | Multivalent and multispecific binding proteins, their production and use |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| DE19539493A1 (en) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Strong homologous promoter from hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CN100405399C (en) | 1999-02-05 | 2008-07-23 | 三星电子株式会社 | Image texture retrieving method and apparatus thereof |
| PE20020574A1 (en) | 2000-12-06 | 2002-07-02 | Wyeth Corp | HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| WO2003057838A2 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| CA2507664C (en) | 2002-11-29 | 2010-09-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
| DE10338531A1 (en) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for recloning production cells |
| DK1820022T3 (en) | 2004-11-10 | 2009-09-14 | Boehringer Ingelheim Pharma | Application of flow cytometric analysis to optimize cell bank strategies of CHO cells |
| US8703096B2 (en) | 2006-04-21 | 2014-04-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Beta-amyloid PET imaging agents |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| MY148472A (en) | 2007-03-02 | 2013-04-30 | Boehringer Ingelheim Pharma | Improvement of protein production |
| EP2031064A1 (en) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for increasing protein titres |
| JP2010195710A (en) * | 2009-02-25 | 2010-09-09 | Kumamoto Univ | Amyloid fibril formation inhibitor and use thereof |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| UA118441C2 (en) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
| WO2014124334A2 (en) * | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| WO2015010118A2 (en) * | 2013-07-19 | 2015-01-22 | The University Of Texas | Transthyretin amyloid-selective and polyreactive catabodies |
-
2016
- 2016-01-27 TW TW109138086A patent/TWI769570B/en active
- 2016-01-27 TW TW105102532A patent/TWI711631B/en active
- 2016-01-28 ES ES16702990T patent/ES2925716T3/en active Active
- 2016-01-28 CA CA2974993A patent/CA2974993A1/en active Pending
- 2016-01-28 SG SG11201706126WA patent/SG11201706126WA/en unknown
- 2016-01-28 HR HRP20220918TT patent/HRP20220918T1/en unknown
- 2016-01-28 WO PCT/IB2016/050416 patent/WO2016120811A1/en active Application Filing
- 2016-01-28 RS RS20220788A patent/RS63513B1/en unknown
- 2016-01-28 PE PE2017001289A patent/PE20180218A1/en unknown
- 2016-01-28 SG SG10201906696RA patent/SG10201906696RA/en unknown
- 2016-01-28 DK DK16702990.9T patent/DK3250593T3/en active
- 2016-01-28 SI SI201631572T patent/SI3250593T1/en unknown
- 2016-01-28 HU HUE16702990A patent/HUE059592T2/en unknown
- 2016-01-28 EA EA201791710A patent/EA036014B1/en unknown
- 2016-01-28 CU CUP2017000098A patent/CU20170098A7/en unknown
- 2016-01-28 KR KR1020177023750A patent/KR102649788B1/en active IP Right Grant
- 2016-01-28 MY MYPI2017702752A patent/MY193701A/en unknown
- 2016-01-28 MX MX2017009803A patent/MX2017009803A/en unknown
- 2016-01-28 PT PT167029909T patent/PT3250593T/en unknown
- 2016-01-28 AU AU2016210889A patent/AU2016210889C1/en active Active
- 2016-01-28 BR BR112017016345A patent/BR112017016345A2/en active Search and Examination
- 2016-01-28 CN CN201680015343.2A patent/CN107406500B/en active Active
- 2016-01-28 PL PL16702990.9T patent/PL3250593T3/en unknown
- 2016-01-28 EP EP16702990.9A patent/EP3250593B1/en active Active
- 2016-01-28 JP JP2017540250A patent/JP7101927B2/en active Active
- 2016-01-28 US US15/009,667 patent/US20160257737A1/en not_active Abandoned
-
2017
- 2017-07-25 SA SA517381981A patent/SA517381981B1/en unknown
- 2017-08-22 CO CONC2017/0008482A patent/CO2017008482A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501318A1 (en) | Anti-transthyretin antibodies | |
| SA517381991B1 (en) | Anti-Transthyretin Antibodies | |
| SA517381981B1 (en) | Anti-transthyretin antibodies | |
| WO2018007924A3 (en) | Anti-transthyretin antibodies | |
| MX2020003041A (en) | Anti-transthyretin antibodies. | |
| WO2018007923A3 (en) | Anti-transthyretin antibodies | |
| WO2018007922A3 (en) | Anti-transthyretin antibodies | |
| MX2020002694A (en) | Antibody molecules to tim-3 and uses thereof. | |
| PH12020550141A1 (en) | Antibody molecules to cd138 and uses thereof | |
| CL2020002468A1 (en) | Antibodies that bind to sortilin and inhibit the binding of progranulin (divisional application 92-2018) | |
| MX2021016098A (en) | Humanized antibody molecules to cd138 and uses thereof. | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| MY193688A (en) | Anti-transthyretin antibodies | |
| EA202090891A1 (en) | ANTIBODY MOLECULES AGAINST CD138 AND THEIR APPLICATION | |
| EA202090898A1 (en) | ANTITRANSTYRETIN ANTIBODIES | |
| PH12020552202A1 (en) | Antibody molecules to complement component 5 and uses thereof | |
| BR112017007112A2 (en) | 1,2-benzothiazole compounds for the treatment of kidney disorders |